Some drugs are going generic this year and next

By Alexia Elejalde-Ruiz

Dozens of brand-name prescription drugs are losing their patent protection, allowing generic versions to enter the market and consumers to save 30 to 80 percent on those medications, said David Belian, director of media relations for the Generic Pharmaceutical Association.

Generic forms of drugs have the same active ingredients as their brand-name counterparts but are significantly cheaper because they don't invest in clinical trials or advertising, Belian said.

About 80 percent of prescriptions are filled with generic drugs, and they have a good track record, said Howard Schiff, executive director of the Maryland Pharmacists Association. But some generic drugs may not work as well as the original brands, so before making the switch consider consulting your doctor who can write a prescription specifying brand-name or generic, Schiff said.

These are the prescription drugs that have been or are expected to be released as generics in 2012 and 2013, according to , which manages pharmacy benefits for employer health plans.

2012: Symbyax (treatment-resistant depression); Geodon (schizophrenia, bipolar disorder); Lexapro (depression, anxiety); Seroquel (schizophrenia, bipolar disorder); Avandia (Type 2 diabetes); Avandamet (Type 2 diabetes); Avandaryl (Type 2 diabetes); Avapro (high blood pressure); Avalide (high blood pressure); Provigil (excessive sleepiness); Plavix (prevents blood clots); Viramune (HIV infection); Lescol/Lescol XL (high cholesterol); Tricor (high cholesterol); Clarinex/Clarinex D (, hives); Singulair (asthma and allergy symptoms); Actos (Type 2 diabetes); Xopenex (asthma, COPD); Revatio (); Diovan/Diovan HCT (high blood pressure); Detrol (); Lidoderm (pain from post-herpetic neuralgia); Atacand/Atacand HCT (); Evoxac (Sjogren's syndrome); Maxalt/Maxalt MLT (migraines); Actoplus Met (Type 2 diabetes).

2013: Opana ER (pain); Zometa (bone complications from cancer); Valcyte (viral infections); Zomig (migraines); Fosamax Plus D (osteoporosis); Rilutek (amyotrophic lateral sclerosis); Temodar (glioblastoma multiforme); Cerezyme (Gaucher disease); Niaspan (high cholesterol); Advicor (); AcipHex (GERD); Vivelle-DOT (menopausal symptoms); Cymbalta (depression, anxiety, nerve/musculoskeletal pain, fibromyalgia).

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Americans turn to generic medications in 2010: report

Apr 22, 2011

(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Global spending on drugs to slow through 2016

Jul 12, 2012

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

US prescription drug use fell in 2008, study says

May 13, 2009

(AP) -- Prescription drug use in the U.S. fell last year, although total spending on drugs increased as prices rose sharply on brand-name products, pharmacy benefits manager Medco Health Solutions said Wednesday.

Drug prices to plummet in wave of expiring patents

Jul 25, 2011

The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top ...

FDA approves first generic versions of Zyprexa

Oct 24, 2011

(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Recommended for you

EU regulator: Morning-after pill OK for all women

10 hours ago

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

14 hours ago

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

Zydelig approved for three types of blood cancer

15 hours ago

(HealthDay)—Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) ...

Journal raises concern about blood-thinning drug

Jul 23, 2014

A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Osiris1
not rated yet Aug 12, 2012
Fosamax will disappear in the wave of lawsuits against its manufacturer. No generic manufacturer in his right mind would ever touch that poison.